Prophylactic Eculizumab Use in Kidney Transplantation: A Review of the Literature and Report of a Case with Atypical Hemolytic Uremic Syndrome


Kasapoglu U., Ruhi C. , Tugcu M., Boynuegri B., Titiz I., Hancer V. S. , ...More

ANNALS OF TRANSPLANTATION, vol.20, 2015 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20
  • Publication Date: 2015
  • Doi Number: 10.12659/aot.894665
  • Title of Journal : ANNALS OF TRANSPLANTATION

Abstract

Background: Atypical hemolytic uremic syndrome (aHUS) is a very rare disease, which presents with microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Progression to end-stage renal disease (ESRD) from acute kidney injury is observed in 60% of aHUS cases. The prognosis of aHUS patients who undergo kidney transplantation (Ktx) is generally poor, but these patients should be treated prophylactically with eculizumab to prevent recurrence after transplantation.